Waterley Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 4.00 M
as on 24-07-2024
- Paid Up Capital ₹ 3.72 M
as on 24-07-2024
- Company Age 10 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 76.36%
(FY 2023)
- Profit 159.46%
(FY 2023)
- Ebitda 129.16%
(FY 2023)
- Net Worth 95.58%
(FY 2023)
- Total Assets 72.51%
(FY 2023)
About Waterley Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.00 M and a paid-up capital of Rs 3.72 M, as per Ministry of Corporate Affairs (MCA) records.
Manish Sutrave, Venu Senagapally, Shinod Parreri, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24232TG2014PTC092812
- Company No.
092812
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Feb 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Secunderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Waterley Pharmaceuticals?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manish Sutrave  | Director | 07-Feb-2014 | Current |
| Venu Senagapally | Director | 07-Feb-2014 | Current |
| Shinod Parreri | Director | 07-Feb-2014 | Current |
| Megamreddy Balling | Director | 25-Sep-2017 | Current |
| Ganesh Kappagantu | Director | 29-Jan-2020 | Current |
Financial Performance of Waterley Pharmaceuticals.
Waterley Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 76.36% increase. The company also saw a substantial improvement in profitability, with a 159.46% increase in profit. The company's net worth Soared by an impressive increase of 95.58%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Waterley Pharmaceuticals?
In 2023, Waterley Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Waterley Pharmaceuticals?
Waterley Pharmaceuticals has a workforce of 83 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Waterley Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Waterley Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
